Pyramid Biosciences and Caris Life Sciences Announce MI Trials Collaboration for Clinical Trial Matching in Support of Study for Patients with NTRK Fusion Solid Tumors
– Molecular Intelligence Trials (MI Trials) collaboration will enhance identification of patients with NTRK fusion-positive solid tumors, including primary and metastatic CNS tumors potentially eligible for enrollment in the ongoing PBI-200-101 Phase 1/2 clinical study
– Pyramid Biosciences currently developing pipeline of clinical-stage precision medicines, including its lead program PBI-200, a next-generation, highly CNS penetrant tropomyosin receptor kinase (TRK) inhibitor for patients with NTRK fusion-driven cancers
– Caris’ innovative precision medicine service designed to maximize access and increase efficiency of clinical trials in precision medicine
Excerpt from the Press Release:
WALTHAM, Mass. and IRVING, Texas, March 10, 2022 /PRNewswire/ — Pyramid Biosciences, Inc., and Caris Life Sciences® (Caris), today announced a collaboration to enhance identification of potential patients with NTRK fusion-driven cancers for participation in the ongoing Phase 1/2 trial (PBI-200-101) of Pyramid’s lead oncology program PBI-200, a best-in-class, next-generation, highly CNS-penetrant TRK inhibitor. Pyramid Biosciences is a clinical-stage biotechnology company developing a portfolio of precision therapies targeting a wide range of diseases. Caris is the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare. Caris’ tailored MI Trials offering helps match the right patients to the right biopharma trials based on both the individual patient’s molecular tumor profile and the eligibility requirements of a given study.
“This collaboration will further advance the promise of precision oncology, with the potential to deliver highly differentiated compounds against validated cancer targets,” said Brian Lestini, M.D., Ph.D., Chief Executive Officer of Pyramid Bio. “Caris’ patient identification and matching service is invaluable for enabling the development of novel precision therapies, especially in genetically-defined populations like NTRK.”
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?